Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
ALPHARETTA, Ga., March 07, 2017 -- Clearside Biomedical, Inc. (NASDAQ:CLSD) (“Clearside” or the “Company”), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, announced today that its fourth quarter and full year 2016 financial results will be released at 7:00 a.m. on Tuesday, March 14, 2017. Following the release, Clearside will host a live conference call and webcast at 8:30 a.m. ET to discuss the Company’s financial results and provide a general business and strategic review.
The live webcast and a replay may be accessed by visiting the “Investor Relations” section at www.clearsidebio.com. Alternately, please call (844) 263-8310 (U.S.) or (213) 358-0959 (international) to participate in the live conference call. The conference ID number for the live call is 84209729. Please dial in approximately 10 minutes prior to the call. An archive of the webcast will be available until April 13, 2017.
About Clearside Biomedical, Inc.
Clearside Biomedical, Inc., headquartered in Alpharetta, GA, is a late-stage clinical ophthalmic biopharmaceutical company that envisions a world without blindness. Clearside relentlessly pursues transformative, elegant, precise solutions to restore and preserve vision. Clearside is developing advanced clinical and pre-clinical candidates using a proprietary treatment approach offering unprecedented access to the back of the eye through the suprachoroidal space (SCS™). This offers potentially meaningful treatment benefit to patients suffering from sight threatening diseases like uveitis, retinal vein occlusion, diabetic macular edema and wet age-related macular degeneration. To learn more about how Clearside is changing ophthalmology, please visit us at www.clearsidebio.com.
Contacts: Stephen Kilmer Investor Relations (678) 270-3631 [email protected] Charles Deignan Chief Financial Officer 678-270-4005 [email protected]
